Global Guillain-Barré Syndrome (GBS) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Guillain-Barré Syndrome (GBS) Market Size

• The global Guillain-Barré Syndrome (GBS) market size was valued at USD 724.16 million in 2024 and is expected to reach USD 1.09 billion by 2032, at a CAGR of 5.30% during the forecast period
• This growth is driven by factors such as the increasing awareness, advancements in treatment options, and a rising incidence of autoimmune diseases and infections such as  Zika and influenza that trigger GBS

Guillain-Barré Syndrome (GBS) Market Analysis

• Guillain-Barré Syndrome (GBS) is a rare neurological disorder where the body’s immune system attacks the peripheral nerves, often triggered by infections such as Zika virus, influenza, or Campylobacter jejuni
• The market growth is primarily driven by rising incidence of autoimmune and infectious diseases, increased awareness, and advances in early diagnosis and immunotherapy treatments
• North America is expected to dominate the global GBS market owing to high healthcare expenditure, supportive regulatory frameworks, and access to advanced treatment options
• Asia-Pacific is expected to be the fastest growing region in the Guillain-Barré Syndrome (GBS) market during the forecast period due to improving healthcare infrastructure, growing patient awareness, and increasing prevalence of GBS-related infections
• Acute Inflammatory Demyelinating Polyneuropathy (AIDP) segment is expected to dominate the market with a market share of 60.2% due to its high prevalence. AIDP is the most common form of Guillain-Barré Syndrome, characterized by rapid onset muscle weakness caused by damage to the myelin sheath. Early diagnosis and availability of effective treatments such as IVIG and plasmapheresis further support its market dominance

Report Scope and Guillain-Barré Syndrome (GBS) Market Segmentation         

Guillain-Barré Syndrome (GBS) Market Trends

“Rising Adoption of Advanced Immunotherapies and Diagnostic Technologies”

• One prominent trend in the Guillain-Barré syndrome market is the growing adoption of advanced immunotherapies and diagnostic technologies aimed at improving treatment efficacy and early detection
• These emerging biologics and refined IVIG formulations are enhancing therapeutic outcomes by reducing disease progression and recovery time

• For instance, novel immunomodulatory treatments and biomarker-based diagnostic tools are enabling earlier intervention and more personalized treatment plans, significantly improving prognosis in severe GBS cases

• These advancements are reshaping the GBS treatment landscape, supporting market growth by increasing the accessibility and effectiveness of care across diverse healthcare settings

Guillain-Barré Syndrome (GBS) Market Dynamics

Driver

“Rising Incidence of Infectious Diseases and Autoimmune Disorders”

• The increasing incidence of infections such as Zika virus, Campylobacter jejuni, and influenza—common triggers for Guillain-Barré syndrome—is a major factor driving market growth
• These infections can initiate an abnormal immune response, leading to the onset of GBS, thereby increasing the demand for timely diagnosis and effective treatment
• With growing global health concerns around emerging viral outbreaks and autoimmune conditions, healthcare systems are focusing more on rapid diagnostic techniques and accessible immunotherapies for GBS

For instance,

• According to the CDC, outbreaks of Zika virus have been linked to increased GBS cases, especially during the 2015–2016 epidemic in the Americas, highlighting the correlation between infectious diseases and GBS prevalence

• As the global burden of infectious and autoimmune diseases continues to rise, so does the need for efficient GBS management, driving demand for therapeutic and diagnostic advancements

Opportunity

“Emergence of Precision Medicine and Biomarker-Based Diagnostics”

• The integration of precision medicine and biomarker-based diagnostics presents a significant opportunity for improving the diagnosis and management of Guillain-Barré syndrome
• Advanced molecular and genetic testing can help identify patient-specific biomarkers, enabling earlier detection, personalized treatment plans, and better prediction of disease progression
• These technologies also support the development of targeted therapies that can modulate immune responses more effectively and reduce long-term neurological complications

For instance,

• A 2024 study published in Nature Reviews Neurology highlighted the role of cerebrospinal fluid biomarkers in predicting GBS severity and treatment response, opening avenues for tailored immunotherapy strategies and improving patient outcome

• The adoption of precision medicine in GBS care has the potential to transform traditional treatment approaches, improve therapeutic efficacy, and reduce healthcare costs by focusing on individualized care

Restraint/Challenge

“Limited Access to Advanced Treatment in Low-Resource Settings”

• The limited availability and high cost of advanced treatments such as intravenous immunoglobulin (IVIG) and plasmapheresis pose significant challenges in low- and middle-income countries
• These therapies require specialized equipment, trained personnel, and high financial investment, which are often lacking in under-resourced healthcare systems
• As a result, delayed or suboptimal treatment of GBS can lead to prolonged recovery, increased complications, or even permanent disability

For instance,

• According to a 2023 article published in The Lancet Neurology, many regions in Africa and parts of Southeast Asia report inconsistent access to immunotherapy for GBS, often relying on supportive care alone due to cost constraints and supply shortages

• This lack of access creates disparities in treatment outcomes and poses a significant barrier to market expansion, highlighting the need for affordable and scalable treatment solutions.

Guillain-Barré Syndrome (GBS) Market Scope

The market is segmented on the basis of type, therapeutics, route of administration, diagnosis, treatment, end user, and distribution channel

In 2025, the acute inflammatory demyelinating polyneuropathy (AIDP) is projected to dominate the market with a largest share in type segment

The acute inflammatory demyelinating polyneuropathy (AIDP) segment is expected to dominate the Guillain-Barré Syndrome (GBS) market with the largest share of 60.2% in 2025 due to its high prevalence. AIDP is the most common form of Guillain-Barré syndrome, characterized by rapid onset muscle weakness caused by damage to the myelin sheath. Early diagnosis and availability of effective treatments such as IVIG and plasmapheresis further support its market dominance

The intravenous is expected to account for the largest share during the forecast period in therapeutics market

In 2025, the intravenous segment is expected to dominate the market with the largest market share of 52.85% due to its rapid and effective delivery of immunoglobulin therapies, which are the frontline treatment for Guillain-Barré syndrome. Intravenous administration ensures faster absorption and immediate therapeutic impact, which is critical in managing acute symptoms and preventing complications. In addition, its widespread use in hospitals and growing adoption in outpatient care settings further contribute to its market leadership

Guillain-Barré Syndrome (GBS) Market Regional Analysis

“North America Holds the Largest Share in the Guillain-Barré Syndrome (GBS) Market”

• North America dominates the global GBS market due to the region’s robust healthcare infrastructure, high awareness levels, and early adoption of advanced immunotherapies such as IVIG and plasmapheresis
• U.S. accounts for the largest market share, supported by strong research initiatives, a high prevalence of autoimmune disorders, and favorable reimbursement policies for rare disease treatments
• In addition, the presence of leading pharmaceutical companies, government support for neurological research, and a well-established diagnostic network significantly enhance patient access to timely and effective treatment
• The growing focus on personalized medicine and availability of clinical trial data further contribute to the region’s leadership in the GBS market

“Asia-Pacific is Projected to Register the Highest CAGR in the Guillain-Barré Syndrome (GBS) Market”

• Asia-Pacific is expected to witness the fastest growth in the GBS market, driven by increasing healthcare spending, improved diagnostic capabilities, and a rising burden of infectious diseases linked to GBS onset
• Countries such as China, India, and Japan are key contributors due to growing awareness of neurological conditions and the rising availability of immunoglobulin therapies
• Japan, with its advanced healthcare system and emphasis on early diagnosis and intervention, continues to adopt emerging therapies for rare neurological disorders
• In China and India, the increasing prevalence of GBS-associated infections such as Campylobacter jejuni and Zika, combined with expanding healthcare infrastructure and policy support for rare diseases, is accelerating market growth

Guillain-Barré Syndrome (GBS) Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Grifols, S.A. (Spain)
• CSL (Australia)
• Octapharma AG (Switzerland)
• Baxter (U.S.)
• Kedrion (Italy)
• Biotest AG (Germany)
• LFB (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Bristol-Myers Squibb (U.S.)
• Sanofi (France)
• Novo Nordisk A/S (Denmark)
• Sobi (Swedish Orphan Biovitrum) (Sweden)
• Alexion Pharmaceuticals, Inc. (U.S.)
• Lilly (U.S.)
• Regeneron Pharmaceuticals Inc. (U.S.)

Latest Developments in Global Guillain-Barré Syndrome (GBS) Market

• In February 2025, Grifols announced positive results from a Phase 2/3 clinical trial of its subcutaneous immunoglobulin (SCIg) therapy for GBS. The study demonstrated improved physical performance in patients, as measured by the two-minute walk distance (2MWD), after one year of treatment. This advancement offers a more convenient and potentially effective alternative to traditional intravenous immunoglobulin (IVIG) therapy
• In December 2024, CSL Behring initiated a strategic partnership with leading academic hospitals in Europe to advance research on GBS biomarkers and personalized immunotherapy approaches. The initiative focuses on early identification of severe cases and tailoring treatment based on patient-specific immune response profiles
• In November 2024, the U.S. National Institute of Neurological Disorders and Stroke (NINDS) funded a multi-center study to develop AI-powered diagnostic models for Guillain-Barré Syndrome. This project aims to leverage machine learning to analyze clinical and electrophysiological data, improving early detection and prognosis prediction
• In October 2024, Octapharma AG received FDA Fast Track designation for its novel immunoglobulin therapy, OctaGBS, developed specifically for GBS. The therapy is designed to enhance immune modulation with a faster onset of action, and Phase II trials are currently underway, with promising interim safety and efficacy data 

SKU-46213